Clinical TrialJun 15, 2026, 06:12 AM
Ascendis Pharma TransCon PTH Phase 3 shows sustained efficacy at Week 182
AI Summary
Ascendis Pharma announced positive Week 182 data from its completed Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The long-term treatment demonstrated sustained efficacy and safety over three and a half years, replicating endogenous PTH actions across target organ systems. Patients showed improved quality of life, normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density, while achieving independence from conventional therapy. The treatment was generally well-tolerated with no new safety signals.
Key Highlights
- 86% of patients were responders for the multi-component endpoint.
- 100% of patients achieved independence from active vitamin D.
- 96% of patients achieved independence from therapeutic calcium doses.
- Mean eGFR increased by 11.0 mL/min/1.73 m2 from baseline, maintained at 80.2.
- Mean 24-hour urine calcium normalized and remained normal through Week 182.
- No new safety signals identified; no discontinuations related to study drug.
- No patients developed anti-PTH antibodies over three and a half years.
- 89% of patients completed the three-and-a-half-year trial.
Price Impact
More from ASND